Ira Duarte - 19 Jul 2025 Form 4 Insider Report for HERON THERAPEUTICS, INC. /DE/ (HRTX)

Role
EVP, Chief Financial Officer
Signature
/s/Kathryn Lester Attorney-in-fact for Ira Duarte
Issuer symbol
HRTX
Transactions as of
19 Jul 2025
Net transactions value
$0
Form type
4
Filing time
04 Aug 2025, 17:27:04 UTC
Previous filing
25 Jun 2025
Next filing
21 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Duarte Ira EVP, Chief Financial Officer 100 REGENCY FOREST DRIVE, SUITE 300, CARY /s/Kathryn Lester Attorney-in-fact for Ira Duarte 04 Aug 2025 0001488864

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HRTX Common Stock Options Exercise +11,695 +7.7% 164,218 31 Jul 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HRTX Restricted Stock Units Options Exercise $0 -11,695 -6.7% $0.000000 163,721 31 Jul 2025 Common Stock 11,695 $0.000000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock.
F2 The number of restricted stock units disclosed on the Reporting Person's Form 4 filed on April 22, 2025, May 2, 2025 and June 17 , 2025 ("Affected Form 4 Filings") were erroneously disclosed as an acquisition in Column 5(A) when it should have been disclosed as a disposition in Column 5(D). All other information in the Affected Form 4 Filings is correct.
F3 The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).